Immunoprophylaxis of perinatal transmission of the hepatitis B virus: efficacy of hepatitis B immune globulin and hepatitis B vaccine in a low-prevalence area. 1986

J I Esteban, and J Genesca, and R Esteban, and J M Hernandez, and G Seijo, and M Buti, and R Muniz, and J Guardia

One hundred eleven newborn infants born of Spanish hepatitis B surface antigen (HBsAg) carrier mothers were consecutively assigned to one of three treatment groups. Group A was treated with three or four doses of hepatitis B immune globulin (HBIG) in one of three different schedules. Group B received one dose of hepatitis B vaccine (Hevac-B, Pasteur) at birth and at 1, 2 and 12 months. Group C was treated with the same vaccination schedule as group B and in addition received a single dose of HBIG at birth. Comparisons were made in the 85 babies who had strictly completed the immunization schedule and had been followed for at least 12 months. The three immunization protocols were equally effective, since none of the children became a chronic HBsAg carrier or developed acute symptomatic infection. There were five transient and subclinical infections among children who received only HBIG (group A), one transient infection in group B, and one in group C. There seems to be some correlation between anti-HBs levels and degree of protection, since all transient infections in group A occurred in the subgroups who did not maintain protective antibodies during the first 6 months. Although the percentage of responders in the two vaccinated groups did not differ significantly, children who received only vaccine reached higher antibody levels than those who also received HBIG. Our results suggest that any immunization schedule able to maintain anti-HBs levels during the first 6 months of life would be useful to prevent mother-to-infant transmission of the hepatitis B virus in areas where most of the carrier women are expected to be anti-HBe positive and hence relatively less infectious.

UI MeSH Term Description Entries
D007110 Immunity, Active Resistance to a disease agent resulting from the production of specific antibodies by the host, either after exposure to the disease or after vaccination. Active Immune Response,Active Immune Responses,Active Immunities,Active Immunity,Immune Response, Active,Immune Responses, Active,Immunities, Active,Response, Active Immune,Responses, Active Immune
D007116 Immunization, Passive Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER). Convalescent Plasma Therapy,Immunoglobulin Therapy,Immunotherapy, Passive,Normal Serum Globulin Therapy,Passive Antibody Transfer,Passive Transfer of Immunity,Serotherapy,Passive Immunotherapy,Therapy, Immunoglobulin,Antibody Transfer, Passive,Passive Immunization,Therapy, Convalescent Plasma,Transfer, Passive Antibody
D007136 Immunoglobulins Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses. Globulins, Immune,Immune Globulin,Immune Globulins,Immunoglobulin,Globulin, Immune
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008297 Male Males
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011251 Pregnancy Complications, Infectious The co-occurrence of pregnancy and an INFECTION. The infection may precede or follow FERTILIZATION. Complications, Infectious Pregnancy,Infectious Pregnancy Complications,Maternal Sepsis,Pregnancy, Infectious Complications,Sepsis during Pregnancy,Sepsis in Pregnancy,Infectious Pregnancy Complication,Pregnancy Complication, Infectious,Sepsis in Pregnancies,Sepsis, Maternal
D002353 Carrier State The condition of harboring an infective organism without manifesting symptoms of infection. The organism must be readily transmissible to another susceptible host. Asymptomatic Carrier State,Asymptomatic Infection Carrier,Inapparent Infection Carrier,Presymptomatic Carrier State,Presymptomatic Infection Carrier,Super-spreader Carrier,Superspreader Carrier,Asymptomatic Carrier States,Asymptomatic Infection Carriers,Carrier State, Asymptomatic,Carrier State, Presymptomatic,Carrier States,Carrier, Super-spreader,Carrier, Superspreader,Carriers, Super-spreader,Carriers, Superspreader,Inapparent Infection Carriers,Infection Carrier, Asymptomatic,Infection Carrier, Inapparent,Infection Carrier, Presymptomatic,Presymptomatic Carrier States,Presymptomatic Infection Carriers,Super spreader Carrier,Super-spreader Carriers,Superspreader Carriers
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic

Related Publications

J I Esteban, and J Genesca, and R Esteban, and J M Hernandez, and G Seijo, and M Buti, and R Muniz, and J Guardia
May 1987, JAMA,
J I Esteban, and J Genesca, and R Esteban, and J M Hernandez, and G Seijo, and M Buti, and R Muniz, and J Guardia
August 1984, Gastroenterology,
J I Esteban, and J Genesca, and R Esteban, and J M Hernandez, and G Seijo, and M Buti, and R Muniz, and J Guardia
May 2003, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi,
J I Esteban, and J Genesca, and R Esteban, and J M Hernandez, and G Seijo, and M Buti, and R Muniz, and J Guardia
October 1997, The Journal of family practice,
J I Esteban, and J Genesca, and R Esteban, and J M Hernandez, and G Seijo, and M Buti, and R Muniz, and J Guardia
April 1986, Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
J I Esteban, and J Genesca, and R Esteban, and J M Hernandez, and G Seijo, and M Buti, and R Muniz, and J Guardia
April 1987, Journal of medical virology,
J I Esteban, and J Genesca, and R Esteban, and J M Hernandez, and G Seijo, and M Buti, and R Muniz, and J Guardia
January 1983, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
J I Esteban, and J Genesca, and R Esteban, and J M Hernandez, and G Seijo, and M Buti, and R Muniz, and J Guardia
July 1986, The Journal of infection,
J I Esteban, and J Genesca, and R Esteban, and J M Hernandez, and G Seijo, and M Buti, and R Muniz, and J Guardia
September 1991, Minerva ginecologica,
J I Esteban, and J Genesca, and R Esteban, and J M Hernandez, and G Seijo, and M Buti, and R Muniz, and J Guardia
June 2003, Journal of medical virology,
Copied contents to your clipboard!